10月30日 - ** Sensei Biotherapeutics SNSE.O开盘后股价上涨1.6%至9.38美元
** 该公司表示将停止开发试验性抗癌药物solnerstotug，并开始对战略选择进行审查
** 公司表示，选择可能包括出售公司、资产或结束运营
** 将董事会的决定归因于未来研究的成本和严峻的市场条件
** SNSE 将裁员，只保留一个小团队来协助审查工作，并管理正在进行的临床试验的停工事宜。
** 截至6月30日，公司拥有2860万美元的现金、现金等价物和有价证券
** 截至上次收盘，股价年累计下跌约 4
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.